Optigenex Inc. Enters Into Exclusive Supply and Trademark Agreements and Grants Sub-Licensing Rights to RFI, LLC of Blauvelt, Ne
August 11 2008 - 8:30AM
PR Newswire (US)
RFI grants exclusive sublicense to GeneWize Life Sciences, a wholly
owned subsidiary of GeneLink, Inc. to market AC-11(R) in the
Affiliate Direct Selling Channel NEW YORK, Aug. 11
/PRNewswire-FirstCall/ -- Optigenex Inc. (OTC:OPGX.OB) (BULLETIN
BOARD: OPGX.OB) announced today the signing with RFI, LLC of two
exclusive Supply and Trademark License Agreements for the territory
of North America to market AC-11(R). The Agreement will allow RFI,
LLC to market products under the registered trademark AC-11(R)
(Formerly known as C-Med- 100(R)) and capitalize on the
scientifically validated qualities of the patented AC-11(R)
compound. In third party pre-clinical and scientific studies,
AC-11(R) has been shown to help the body's natural ability to
repair damage to DNA due to multiple causes, including the harmful
effects of UV radiation from exposure to the sun, stress, toxins
and environmental pollution. Additional studies moreover have
established the effectiveness of AC-11(R) as an inhibitor of
pro-inflammatory agents, and as a natural immune stimulator. Jeff
Wuagneux, President and CEO of RFI, LLC, said, "RFI and our
Sub-Licensee GeneWize, a wholly owned subsidiary of GeneLink, Inc.
(OTC Bulletin Board: GNLK.OB) are particularly enthusiastic about
the present and future prospects related to AC-11(R) based formulas
for distribution into the Direct to Healthcare Practitioner channel
under RFI's PhytoRich brand as well as a primary component of the
GeneWize Direct Selling genetic testing model, and we are fortunate
to have aligned ourselves with a reputable science based company
such as Optigenex." Daniel Zwiren, President and CEO of Optigenex
Inc., said, "The signing of these two agreements marks a
significant milestone for Optigenex Inc. towards our goal of
achieving brand awareness and continued validation of our
technology through the adoption by market leaders. RFI has devoted
significant time and resources in positioning AC-11(R) with a
company that owns patented technology focused on targeting a unique
supplement program based on a specific and personal genetic
profile. We believe the future of the dietary supplement industry
will focus on targeted supplement programs and we are confident
that AC-11(R) will play an important role in the years ahead."
Financial Terms Were Not Disclosed. About RFI, LLC: RFI, LLC is a
U.S. based (New York, Colorado) Life Science Development and
Commercialization Company offering a Pipeline of Novel Compounds
and proprietary science-based nutritional bioactive formulas for
the Food, Dietary Supplement, Practitioner, Direct Selling and
Direct to Consumer channels. About Optigenex Inc.: Optigenex Inc.
is a formulator, distributor and provider of proprietary next
generation skin care, supplements and bulk product featuring
AC-11(R), its patented compound, as its core ingredient. AC-11(R)
is the bioactive form of the medicinal herb Uncaria tomentosa. In
data derived from over 10 years of pre-clinical and scientific
study and development, AC-11(R) has been shown to help the body's
natural ability to repair its own DNA, enhance the immune system
function and inhibit pro-inflammatory agents. For more information
about Optigenex please visit the company's website at
http://www.optigenex.com/ NOTE: These statements have not been
evaluated by the Food and drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease.
DATASOURCE: Optigenex Inc. CONTACT: Dan Zwiren of Optigenex Inc.,
+1-201-638-3810 Web site: http://www.optigenex.com/
Copyright